{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:11:51Z","timestamp":1788307911883,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32293231"],"award-info":[{"award-number":["32293231"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31900541"],"award-info":[{"award-number":["31900541"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ajpath.2025.06.012","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T23:35:14Z","timestamp":1753313714000},"page":"1822-1838","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Peroxisome Proliferator\u2013Activated Receptor Agonist IVA337 Alleviates Inflammation and Fibrosis in MASH by Restoring Lipid Homeostasis"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3189-1283","authenticated-orcid":false,"given":"Na","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7569-3986","authenticated-orcid":false,"given":"Shuai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kisseleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2025.06.012_bib1","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 Global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nrd.2015.3","article-title":"Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies","volume":"15","author":"Musso","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ajpath.2025.06.012_bib3","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/antiox10111734","article-title":"Peroxisome proliferator-activated receptors (PPARs) and oxidative stress in physiological conditions and in cancer","volume":"10","author":"Muzio","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.ajpath.2025.06.012_bib4","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2025.06.012_bib5","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.06.012_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib8","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2025.06.012_bib9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.14218\/JCTH.2023.00334","article-title":"An overview of the role of peroxisome proliferator-activated receptors in liver diseases","volume":"11","author":"Changizi","year":"2023","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab"},{"key":"10.1016\/j.ajpath.2025.06.012_bib11","doi-asserted-by":"crossref","first-page":"28488","DOI":"10.1074\/jbc.M004029200","article-title":"Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene","volume":"275","author":"Kersten","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2025.06.012_bib12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI6223","article-title":"Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting","volume":"103","author":"Kersten","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ajpath.2025.06.012_bib13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0020294","article-title":"Regulation of muscle fiber type and running endurance by PPARdelta","volume":"2","author":"Wang","year":"2004","journal-title":"PLoS Biol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib15","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1074\/jbc.M110.138115","article-title":"Role of peroxisome proliferator-activated receptor [delta]\/[beta] in hepatic metabolic regulation","volume":"286","author":"Liu","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2025.06.012_bib16","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from liver fibrosis by a peroxisome proliferator-activated receptor [delta] agonist","volume":"109","author":"Iwaisako","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2025.06.012_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3390\/biomedicines9040365","article-title":"Hepatic stellate cell activation and inactivation in NASH-fibrosis-roles as putative treatment targets?","volume":"9","author":"Zisser","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ajpath.2025.06.012_bib18","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1101\/gad.349232.121","article-title":"Isoform-specific functions of PPAR[gamma] in gene regulation and metabolism","volume":"36","author":"Hu","year":"2022","journal-title":"Genes Dev"},{"key":"10.1016\/j.ajpath.2025.06.012_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1042\/BJ20041896","article-title":"A role for PPARalpha in the control of SREBP activity and lipid synthesis in the liver","volume":"389","author":"Knight","year":"2005","journal-title":"Biochem J"},{"key":"10.1016\/j.ajpath.2025.06.012_bib20","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1074\/jbc.M113.541110","article-title":"Sterol regulatory element-binding protein-1 (SREBP-1) is required to regulate glycogen synthesis and gluconeogenic gene expression in mouse liver","volume":"289","author":"Ruiz","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2025.06.012_bib21","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1210\/me.2002-0191","article-title":"Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling","volume":"17","author":"Ide","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib22","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.3390\/ijms22158298","article-title":"PPARs as metabolic sensors and therapeutic targets in liver diseases","volume":"22","author":"Monroy-Ramirez","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajpath.2025.06.012_bib23","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1073\/pnas.95.8.4333","article-title":"ADD1\/SREBP1 activates PPARgamma through the production of endogenous ligand","volume":"95","author":"Kim","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ajpath.2025.06.012_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/10799893.2021.1905665","article-title":"SIRT1\/NF[kappa]B pathway mediates anti-inflammatory and anti-apoptotic effects of rosmarinic acid on in a mouse model of nonalcoholic steatohepatitis (NASH)","volume":"42","author":"Komeili-Movahhed","year":"2022","journal-title":"J Recept Signal Transduct Res"},{"key":"10.1016\/j.ajpath.2025.06.012_bib25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12072-015-9633-1","article-title":"Comparative clinical study between the effect of fenofibrate alone and its combination with pentoxifylline on biochemical parameters and liver stiffness in patients with non-alcoholic fatty liver disease","volume":"9","author":"El-Haggar","year":"2015","journal-title":"Hepatol Int"},{"key":"10.1016\/j.ajpath.2025.06.012_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/cells9010037","article-title":"Anti-NASH drug development hitches a lift on PPAR agonism","volume":"9","author":"Boeckmans","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.ajpath.2025.06.012_bib27","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3858\/emm.2012.44.10.066","article-title":"Peroxisome proliferator-activated receptor [delta] agonist attenuates hepatic steatosis by anti-inflammatory mechanism","volume":"44","author":"Lee","year":"2012","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.ajpath.2025.06.012_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1210\/jc.2003-031315","article-title":"Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients","volume":"89","author":"Bajaj","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ajpath.2025.06.012_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/cells9020352","article-title":"PPAR-mediated toxicology and applied pharmacology","volume":"9","author":"Xi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ajpath.2025.06.012_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0009-2797(02)00054-6","article-title":"Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors","volume":"142","author":"Lloyd","year":"2002","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.ajpath.2025.06.012_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jep.2016.05.033","article-title":"Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-[alpha]\/[gamma] and attenuating endoplasmic reticulum stress in rats","volume":"189","author":"Ge","year":"2016","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/gerona\/glv043","article-title":"Effects of MHY908, a new synthetic PPAR[alpha]\/[gamma] dual agonist, on inflammatory responses and insulin resistance in aged rats","volume":"71","author":"Park","year":"2016","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.ajpath.2025.06.012_bib33","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-[alpha] and -[delta], induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.06.012_bib34","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3390\/antiox12081523","article-title":"Functional and structural insights into the human PPAR[alpha]\/[delta]\/[gamma] targeting preferences of anti-NASH investigational drugs, lanifibranor, seladelpar, and elafibranor","volume":"12","author":"Kamata","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.ajpath.2025.06.012_bib35","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ajpath.2025.06.012_bib36","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2025.06.012_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103111","article-title":"Protocol to generate human liver spheroids to study liver fibrosis induced by metabolic stress","volume":"5","author":"Kim","year":"2024","journal-title":"STAR Protoc"},{"key":"10.1016\/j.ajpath.2025.06.012_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102391","article-title":"Isolation of primary human liver cells from normal and nonalcoholic steatohepatitis livers","volume":"4","author":"Liu","year":"2023","journal-title":"STAR Protoc"},{"key":"10.1016\/j.ajpath.2025.06.012_bib40","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2020.01.027","article-title":"Identification of lineage-specific transcription factors that prevent activation of hepatic stellate cells and promote fibrosis resolution","volume":"158","author":"Liu","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajpath.2025.06.012_bib41","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cell.2014.10.010","article-title":"iDISCO: a simple, rapid method to immunolabel large tissue samples for volume imaging","volume":"159","author":"Renier","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ajpath.2025.06.012_bib42","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jcmgh.2023.02.010","article-title":"Hepatic stellate cells: dictating outcome in nonalcoholic fatty liver disease","volume":"15","author":"Wiering","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib43","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1021\/acs.molpharmaceut.0c00633","article-title":"SB431542-loaded liposomes alleviate liver fibrosis by suppressing TGF-[beta] signaling","volume":"17","author":"Zhang","year":"2020","journal-title":"Mol Pharm"},{"key":"10.1016\/j.ajpath.2025.06.012_bib44","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41401-022-00860-3","article-title":"Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis","volume":"43","author":"Yang","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.ajpath.2025.06.012_bib45","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ajpath.2025.06.012_bib46","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1161\/ATVBAHA.117.309660","article-title":"[delta]-5 fatty acid desaturase FADS1 impacts metabolic disease by balancing proinflammatory and proresolving lipid mediators","volume":"38","author":"Gromovsky","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ajpath.2025.06.012_bib47","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hep4.1629","article-title":"Fatty acid desaturase 1 influences hepatic lipid homeostasis by modulating the PPAR[alpha]-FGF21 axis","volume":"5","author":"Athinarayanan","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.ajpath.2025.06.012_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188837","article-title":"Acetyl-CoA regulates lipid metabolism and histone acetylation modification in cancer","volume":"1878","author":"He","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.ajpath.2025.06.012_bib49","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2147\/JHC.S418429","article-title":"Downregulated acetyl-CoA acyltransferase 2 promoted the progression of hepatocellular carcinoma and participated in the formation of immunosuppressive microenvironment","volume":"10","author":"Wu","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ajpath.2025.06.012_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13835-w","article-title":"HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXR[alpha] and PPAR[alpha] dysregulation: implications for HIV-specific pathogenesis of NAFLD","volume":"7","author":"Agarwal","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajpath.2025.06.012_bib51","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.7150\/ijbs.71781","article-title":"Egr1 confers protection against acetaminophen-induced hepatotoxicity via transcriptional upregulating of Acaa2","volume":"18","author":"Lei","year":"2022","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.ajpath.2025.06.012_bib52","doi-asserted-by":"crossref","first-page":"11816","DOI":"10.1096\/fj.202000678R","article-title":"Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD","volume":"34","author":"Weber","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.ajpath.2025.06.012_bib53","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2147\/JHC.S338353","article-title":"Acyl-CoA thioesterase 7 is transcriptionally activated by Kr\u00fcppel-like factor 13 and promotes the progression of hepatocellular carcinoma","volume":"8","author":"Xie","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.ajpath.2025.06.012_bib54","article-title":"Knockdown of ACOT4 alleviates gluconeogenesis and lipid accumulation in hepatocytes","volume":"10","author":"Yuan","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ajpath.2025.06.012_bib55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41574-023-00845-0","article-title":"Lipid droplet biogenesis and functions in health and disease","volume":"19","author":"Zadoorian","year":"2023","journal-title":"Nat Rev Endocrinol"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944025002512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944025002512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:18:58Z","timestamp":1777382338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944025002512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0002944025002512"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2025.06.012","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peroxisome Proliferator\u2013Activated Receptor Agonist IVA337 Alleviates Inflammation and Fibrosis in MASH by Restoring Lipid Homeostasis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2025.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}